Di(isononyl)cyclohexane-1,2-dicarboxylate (DINCH) is used as an alternative for some phthalate plasticizers. In rats, DINCH mostly eliminates in feces as cyclohexane-1,2-dicarboxylic acid (CHDA), mono isononyl ester (MINCH) or in urine as CHDA. However, CHDA is not a specific biomarker of DINCH and measuring MINCH in feces is impractical. To identify additional potential biomarkers, we administered DINCH (500 mg/kg body weight) in a single subcutaneous (SC) or oral dose to four adult female Sprague-Dawley rats. We collected 24-h urine samples before dosing (to be used as controls) and 24-h and 48-h after dosing, and serum at necropsy after 48 h. We positively identified and accurately quantified CHDA and cyclohexane-1,4-dicarboxylic acid, mono hydroxyisononyl ester (MHNCH) using authentic standards. Moreover, we tentatively identified MINCH and 12 oxidative metabolites, including 4 cyclohexane ring oxidation products, based on their mass spectrometric-fragmentation patterns. CHDA and MHNCH levels were higher in the urine collected 24 h after oral than SC administration. By contrast, 48-h after dosing, CHDA urinary levels were similar regardless of the exposure route. We detected all but two of the urine metabolites also in serum. Levels of CHDA and MHNCH in serum were lower than in the two post-dose urine collections. Our results suggest that several urinary oxidative metabolites, specifically CHDA, mono oxoisononyl ester and MHNCH may be used as specific biomarkers of DINCH exposure in humans.
Introduction
Di(isononyl)cyclohexane-1,2-dicarboxylate (DINCH) was first introduced commercially in 2002 as a substitute for phthalate plasticizers in many polyvinyl chloride (PVC) products, such as medical devices, toys and food packaging (CPSC, 2010) . Foods with a high fat content can absorb DINCH from packaging materials (Wadey, 2003; Crespo et al., 2007 Crespo et al., , 2009 Biedermann-Brem et al., 2008; Rothenbacher and Schwack, 2009; Wang et al., 2009) .
In animal studies, DINCH produced fewer adverse health effects than phthalates, but caused renal toxicity and thyroid hyperplasia in rats at high-dose levels (EFSA, 2006) . Despite the structural similarities between DINCH and di-isononyl phthalate (DINP), one of the most commonly used PVC plasticizers (BASF AG, 1999) , their metabolisms differ. In both rats and in humans, DINP requires extensive oxidative metabolism before it is excreted in urine (Silva et al., 2006a; . In rats, DINCH is expected to be excreted mostly in bile as its hydrolytic mono ester cyclohexane-1,2-dicarboxylic acid (CHDA)-mono isononyl ester (MINCH) or in urine as CHDA (EFSA, 2006) . As DINCH is considered a safe substitute for commonly used phthalates such as di-2-ethylhexyl phthalate (DEHP) and DINP, the use of DINCH is on the rise, and exposure in humans may increase as well (Wadey, 2003) .
Biomonitoring or the measuring environmental chemicals or their metabolites in biological samples to assess the internal dose is commonly used in human exposure assessments Sexton et al., 2004; Calafat et al., 2006) . Although no published studies have assessed human exposures to DINCH, researchers have successfully used high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) to identify sensitive biomarkers for exposure assessment to phthalates (Albro et al., 1973; Schmid and Schlatter, 1985; Egestad et al., 1996; Nativelle et al., 1999; Silva et al., 2006a; Kato et al., 2007; . Using this same approach in this study, we tentatively identified several metabolites of DINCH in urine and serum after a single oral or subcutaneous (SC) administration of DINCH to Sprague-Dawley rats. These newly identified DINCH metabolites may serve as effective biomarkers for human-exposure assessment to DINCH.
Materials and methods

Chemicals
Hexamoll DINCH (CAS # 474919-59-0, Z99. 5%, Lot CN0904906), a technical mixture of branched and linear isomers, was a generous gift from the BASF Corporation (Florham Park, NJ, USA). CHDA and cyclohexane-1,4-dicarboxylic acid (1,4-CHDA) were purchased from Sigma Aldrich Laboratories (St. Louis, MO, USA). CHDA-mono hydroxyisononyl ester (MHNCH) and D 4 -MHNCH were generous gifts from Dr. Holger Koch (University of Bochum, Germany). Acetonitrile (HPLC grade), water (HPLC grade) and methanol (99.8%, HPLC grade) were purchased from Caledon (Ontario, Canada). The b-glucuronidase (Escherichia coli-K12) was purchased from Roche Biomedical (Mannheim, Germany).
Animal Experiments
Eight female Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN, USA) aged B60 days, weighing B250 g, were housed individually in clear polycarbonate cages (20 Â 25 Â 47 cm 3 ) with laboratory-grade pine shavings as bedding. This experiment was conducted at the Reproductive Toxicology Animal Facility of the US Environmental Protection Agency (EPA) with a 12:12 light-dark cycle (lights off at 1900 hours), temperature of 20-22 1C, and 45-55% relative humidity. The rats were provided with filtered (5 mm) water and NTP 2000 rat chow ad libitum. After 1 day of acclimation, the rats were weighed; 500 mg of Hexamoll DINCH per kg of body weight (bw) in corn oil was administered SC into the fatty layer between the shoulder blades or orally by gavage. The rats were housed individually in Nalgene metabolism cages (Fisher Scientific, Pittsburgh, PA, USA).
For each rat, 24-h urine samples were collected 1 day before (and used for each rat as its own ''control'') and the 2 subsequent days (i.e., 24 and 48 h) after DINCH administration. On the third day, approximately 48-h after dosing, the rats were euthanized and the serum was collected. The urine and serum samples were placed in polypropylene vials and frozen at À70 1C until shipped on dry ice to the Centers for Disease Control and Prevention's National Center for Environmental Health laboratory. At the laboratory, the urine samples were stored at À70 1C until analyzed. The animal treatment protocol was reviewed and approved by the EPA Internal Animal Care and Use Committee.
Analytical Method
Potential metabolites of DINCH (Table 1) were tentatively identified first by infusing diluted (1:100) urine:water from the first 24-h collection after dosing into a TSQ Vantage triple quadrupole mass spectrometer equipped with accurate mass (AM) capabilities (ThermoFinnigan, San Jose, CA, USA) and scanning for all ions on Q1 from m/z ¼ 70 to m/z ¼ 400 in negative ion mode. The fragmentation patterns of electrospray ionization full scan negative ion mass spectra of the major peaks were analyzed further in normal or AM mode after HPLC separation to identify potential DINCH metabolites (Figure 1 ). CHDA and MHNCH were positively identified using authentic standards.
For quantification of MHNCH and CHDA, urine and serum samples were spiked with the internal standard solution containing 1,4-CHDA and D 4 -MHNCH (Table 1) . The DINCH metabolites were extracted after enzymatic hydrolysis, chromatographically resolved (Figure 1) , and detected by ESI-tandem mass spectrometry as previously described (Silva et al., 2007a) . The method was modified to scan for DINCH metabolites, D 4 -MHNCH and 1,4-CHDA (Table 1) . We did not attempt to characterize the individual isomers in the DINCH technical formulation because people would be exposed to the DINCH technical mixture used in consumer products and not to individual DINCH isomers.
Urine and serum MHNCH and CHDA were quantified using the calibration curves prepared with authentic standards (Table 1) . Thirteen other DINCH metabolites were tentatively identified by analyzing their full scan mass spectra (Figures 2-4 ). To identify potential isobaric compounds, we performed a Q1 scan from m/z ¼ 296 to m/z ¼ 329 in AM mode. The urinary levels of MINCH and 10 side chain oxidized metabolites, and ring hydroxy MINCH were quantified using the MHNCH calibration curve (Table 1) . As accurate quantification without authentic standards is not possible, only relative levels of each metabolite between the study groups (e.g., oral vs SC) or sample collections are presented. We did not attempt to quantify the ring oxidized metabolites. 1,4-CHDA was chosen as the internal standard for the quantification of CHDA because of their structural similarities. CHDA and 1,4-CHDA produced common fragments but eluted at different retention times (Figure 3 ). The limit of detection for both MHNCH and CHDA was 1 ng/ml.
Results
By using authentic standards, we unambiguously identified CHDA and MHNCH. Regardless of exposure route, urinary levels of CHDA, the final hydrolysis product of DINCH, were higher than levels of MHNCH for rats after DINCH administration (Table 2) . Furthermore, urinary CHDA levels varied widely between rats in both dosed groups ( Figure 5 ).
We tentatively identified, from their full scan negative ion-ESI mass spectra, MINCH and 12 urinary oxidative metabolites, including 4 cyclohexane ring oxidized metabolites (Table 1, . No DINCH-specific metabolites were found in the 24-h urine of the rats before dosing (control). MINCH; CHDA-mono oxoisononyl ester (MONCH); and MHNCH produced three major fragments (collision energy ¼ 25 eV) at the mass-to-charge ratios (m/z) of 109, 125 and 153 (Figure 2) . We observed fragments with m/z ¼ 127, 153 and 171 for all CHDA, mono carboxyalkyl ester metabolites (i.e., CHDA-mono carboxyisooctyl ester (MCOCH); CHDAmono carboxyisoheptyl ester (MCHpCH); CHDA-mono carboxyisohexyl ester (MCHxCH); CHDA-mono carboxyisopentyl ester (MCPeCH); CHDA-mono carboxyisobutyl ester (MCBCH) CHDA-mono carboxypropyl ester (MCPrCH); CHDA-mono carboxyethyl ester (MCECH)) (Figure 3 ). In addition, each metabolite produced a side chainspecific fragment (Figures 2-3 (Figure 3) . We did not attempt to characterize the metabolites eluted as single peaks to confirm whether they are individual metabolites or isomeric mixtures.
The urinary and serum levels of CHDA and MHNCH ( Figure 5 ) and relative levels of all other measured metabolites and MHNCH were highly correlated (Pearson correlation coefficient, r40.9, Po0.001; Supplementary Figure S1 ). All DINCH metabolites, except MCECH and MCPrCH were detected in the serum of rats collected after 48 h of dosing.
In orally dosed rats, the mean CHDA levels were 446± 19.7 mg/l (first 24-h urine collection) and 97.2±40.6 mg/l (second 24-h urine collection); the mean MHNCH levels were 5.4 ± 2.8 mg/l (first 24-h urine collection) and 1.6 ± 7.4 (second 24-h urine collection) ( Table 2 ). In the SC dosed rats, the mean CHDA levels were 122.9 ± 52.9 mg/l (first 24-h urine collection) and 98.9 ± 27.6 mg/l (second 24-h urine collection); the mean MHNCH levels were 1.4±1.1 (first 24-h urine collection) mg/l and 0.7±0.2 (second 24-h urine collection) ( Table 2) .
The levels of CHDA, MHNCH and 10 other DINCH metabolites in urine relative to the urinary levels from the first 24-h collection of urine are shown in Figure 6 . Figure 2 . Mass spectra of o-1 oxidative metabolites detected in the urine of female Sprague-Dawley rats dosed once with 500 mg/kg bw DINCH by gavage or subcutaneously. Top: cyclohexane-1,2-dicarboxylic acid (CHDA), mono oxoisononyl ester (MONCH). Bottom: CHDA, mono hydroxyisononyl ester (MHNCH). Structures show only one of the potential isomers for each metabolite. MHNCH was identified using authentic standards.
Discussion
We identified CHDA and MHNCH, using authentic standards, and tentatively identified MINCH and nine side chain and four ring oxidized metabolites of DINCH in the urine of adult female Sprague-Dawley rats after oral and SC administration of a single dose (500 mg/kg bw) of a commercial DINCH preparation. This dose, much higher than doses humans would be expected to encounter from the regular use of DINCH-containing products, was selected to ensure the formation of the metabolites in sufficient amounts to allow for their identification. As expected, because all the metabolites derived from DINCH, their urinary levels were highly correlated.
In agreement with previous findings in rats (EFSA, 2006) , we identified CHDA as the major urinary metabolite of DINCH. However, CHDA is not a unique exposure biomarker for DINCH because CHDA can result from the hydrolysis of multiple esters of CHDA such as di(2-ethylhexyl)cyclohexane-1,2-dicarboxylate. By contrast, the oxidative metabolites of DINCH, which, unlike CHDA, can only be formed from the metabolism of DINCH, would be specific DINCH biomarkers. We detected these oxidative DINCH metabolites after administration of DINCH and found them to be analogous to the oxidative metabolites of DINP (Silva et al., 2006b; . However, while CHDA is excreted in urine as the major DINCH metabolite, PA, the analogous hydrolysis product of DINP and other phthalates, is only a minor metabolite in urine of rats dosed with DINP (McKee et al., 2002; Silva et al., 2006a) . Similarly, unlike for phthalates, MHNCH levels in both 24-h urine collections were o2% of the CHDA levels regardless of the route of exposure. Therefore, these findings suggest that although some similarities in the metabolic routes of DINP Figure 3 . Full scan mass spectrometric fragmentation of cyclohexane-1,2-dicarboxylic acid (CHDA), and its mono carboxyalkyl ester metabolites excreted in the urine of female Sprague-Dawley rats after a single subcutaneous or oral exposure to DINCH (500 mg/kg bw). Structures show only one of the potential isomers for each metabolite (where applicable).
and DINCH appear to exit, at least at these much-higherthan background exposure levels, there are also notable differences. We also observed that the urinary levels of all DINCH metabolites were higher after oral than SC administration of DINCH in the first 24-h urine collection. However, in the second 24-h urine collection, the difference in metabolite levels between the two dosing groups was not as evident. Except for MINCH, the mean concentrations of all measured metabolites after oral dosing were 440% lower in the second 24-h urine collection than in the first 24-h urine collection. These results suggest rapid elimination of DINCH after oral exposure and are in agreement with the results from a study of rats that showed rapid partial absorption of 14 C-DINCH after oral administration but o1% radioactivity remaining 1-week after dosing (EFSA, 2006) . By contrast, we observed a gradual elimination of all metabolites in SC dosed rats, with MPeCH, MONCH and MINCH levels higher in the second 24-h urine collection than the first 24-h urine collection, suggesting longer elimination half-life of DINCH when it is administered SC than orally. Similarly, a recent study on pharmacokinetics of bisphenol A (BPA) showed slower urinary elimination when BPA was administered to the rats SC as opposed to orally (Doerge et al., CHDA or MHNCH were not detected in the control urine collected 0-24-h before dosing. Limit of detection (LOD) for CHDA and MHNCH is 1 ng/ml. 2010). Differences in metabolite concentrations between routes of exposure exist (Tukova et al., 2009; Doerge et al., 2010) . We speculate that after SC administration, DINCH may dissolve in the SC fat tissues and slowly partition into the blood thus delaying the onset of oxidative metabolism, which likely occurs mainly in the liver. MINCH, CHDA, MHNCH and 10 other oxidative metabolites were detected in serum 48-h after dosing. However, the mean serum levels of CHDA and MHNCH were between two and three orders of magnitude lower than the mean urinary levels at both time collections (i.e., 24-and 48-h after DINCH administration). Like for urine, CHDA mean serum levels were higher than MHNCH levels (Table 2) .
Of interest, although all rats were given the same dose of DINCH, levels of CHDA and MHNCH in serum and urine varied widely within the dosed rats, regardless of the administration route. These differences are likely due to differences in absorption, distribution in the body compartments, metabolism and excretion of DINCH and its metabolites within each rat. Similar variability in urinary concentrations after a single oral dose of phthalic acid diesters in rats has been reported before (Silva et al., 2007b (Silva et al., , 2011 .
Our analysis of the metabolites of DINCH in urine of rats dosed with DINCH suggests that measuring the urinary concentrations of CHDA and the DINCH-specific oxidative metabolites, MCOCH, MHNCH and MONCH, may be a suitable approach for assessing DINCH exposure by biomonitoring. However, because, at least in rodents, DINCH appears to be excreted mostly in feces as MINCH (EFSA, 2006) and in urine as CHDA (EFSA, 2006) , the oxidative metabolites of DINCH (e.g., MHNCH) may only serve as sensitive exposure biomarkers when exposures to DINCH would be expected at considerably higher than background levels (e.g., occupational settings or medical interventions, which include the use of enteral feeding, tube systems, catheters and/or breathing masks).
